angiogenesis kidney cancer
Conditions
Interventions
20 patients:
All patients will undergo two PET-scans and will take from week 2-5 every day
400mg sorafenib orally.
10 patients will recieve 200 MBq/10 mg 111In-cG250 in 50 ml isotonic saline/5 %
Hum
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: -Renal cell carcinoma patients planned for surgery (nephrectomy/metastectomy) -Karnofsky > 60 % -age over 18 years -signed informed consent
Exclusion criteria
Exclusion criteria: -Known subtype other than clear cell RCC -Pre-exposure to murine/chimeric antibody therapy -Chemotherapy, immunotherapy or radiation therapy within 4 weeks prior to start of study. Palliative limited field external radiation for fracture prevention is allowed -Diabetes Mellitus
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Secondary objective Immunohistochemical analysis of CA-IX expression, (p)VHL status, HIF1-a, VEGF and PDGF expression, apoptosis and necrosis of surgical specimen, to investigate whether the clinical effect of sorafenib is based on angiogenesis, or if other mechanisms play a role. | — |
Primary
| Measure | Time frame |
|---|---|
| Primary objective To determine the effect of sorafenib treatment on In-111-cG250 uptake of the tumor To determine the effect of sorafenib treatment on In-111-bevacizumab uptake of the tumor | — |
Countries
Netherlands
Outcome results
None listed